Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections

Tedizolid phosphate is the first once-daily oxazolidinone approved by the United States Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is more potent in vitro than linezolid against methicillin-resistant Staphylococcus aureus (MRSA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Ronald G, Michaels, Heidi N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411017/
https://www.ncbi.nlm.nih.gov/pubmed/25960671
http://dx.doi.org/10.2147/IDR.S56691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411017/
https://www.ncbi.nlm.nih.gov/pubmed/25960671
http://dx.doi.org/10.2147/IDR.S56691

Ejemplares similares